Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Buy Rating from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) in a report issued on Friday. The brokerage set a "buy" rating on the biotechnology company's stock.

A number of other equities analysts have also recently weighed in on ADAP. Jones Trading cut Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, April 11th. Barclays cut their target price on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating for the company in a research note on Wednesday. Guggenheim decreased their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a research note on Wednesday, March 26th. HC Wainwright lowered their price target on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Wells Fargo & Company reduced their price objective on shares of Adaptimmune Therapeutics from $1.50 to $1.00 and set an "equal weight" rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1.52.

Adaptimmune Therapeutics Stock Performance

NASDAQ:ADAP opened at $0.26 on Friday. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $68.09 million, a P/E ratio of -1.20 and a beta of 2.86. The firm has a 50-day moving average price of $0.29 and a two-hundred day moving average price of $0.51. Adaptimmune Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.48.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The business had revenue of $7.29 million for the quarter, compared to analyst estimates of $6.55 million. As a group, research analysts expect that Adaptimmune Therapeutics will post -0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several hedge funds have recently modified their holdings of the stock. Long Focus Capital Management LLC increased its position in Adaptimmune Therapeutics by 15.9% during the first quarter. Long Focus Capital Management LLC now owns 23,756,687 shares of the biotechnology company's stock worth $4,680,000 after purchasing an additional 3,262,294 shares during the last quarter. Two Seas Capital LP acquired a new stake in shares of Adaptimmune Therapeutics during the 4th quarter worth $7,992,000. Renaissance Technologies LLC raised its position in shares of Adaptimmune Therapeutics by 52.5% in the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock worth $1,361,000 after buying an additional 869,949 shares during the period. Rock Springs Capital Management LP boosted its holdings in Adaptimmune Therapeutics by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock valued at $1,338,000 after acquiring an additional 58,000 shares during the last quarter. Finally, Jane Street Group LLC grew its position in Adaptimmune Therapeutics by 87.7% during the fourth quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company's stock valued at $176,000 after acquiring an additional 152,780 shares during the period. 31.37% of the stock is owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.